STAAR Surgical Company (STAA)
STAANASDAQ-GMOphthalmic Goods
$23.87
-0.6800 (-2.77%) today
At the close, Nov 10, 4:00 PM ET. After hours $23.87 –
- Market cap
- $1.20bn
- P/E
- 39.8
- EPS, last 4 quarters
- $0.6000
- Dividend yield
- –
- Day range
- $23.26 to $24.30
- 52-week range
- $15.59 to $35.87
- Average volume
- 878.2k
- Previous close
- $24.55
Analysts
5 coveringNo consensus2 buy, 3 hold, 0 sell
Targets a year out average $29.40, +23.2% from here
Earnings
next estimate $-0.0100Next report
Dec 2025
-533.3%
Mar 2026
+1066.7%
Jun 2026
+260.0%
Sep 2026
+420.0%
estimate reported, and the surprise
Financials
| Quarter | Jan 2026 | Apr 2026 | Jul 2026 | Oct 2026 |
|---|---|---|---|---|
| Revenue | $57.80m | $93.52m | $93.53m | $83.41m |
| Gross profit | $43.74m | $68.86m | $69.73m | $59.13m |
| Operating income | -$22.84m | $7.98m | $10.10m | $5.46m |
| Net income | -$18.31m | $5.21m | $8.06m | $5.58m |
Last four quarters: revenue $328.27m, margin 0.2%, free cash flow $17.85m
News
8 latest- STAAR Surgical (STAA) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- What STAAR Surgical (STAA) Said on Its Q3 Earnings CallMarketBeat · 6 days ago
- Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue EstimatesZacks · 6 days ago
- Merit Medical (MMSI) Q3 Earnings and Revenues Beat EstimatesZacks · Oct 29, 2026
- Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to DeclineZacks · Oct 28, 2026
- Why Staar Surgical Zoomed Almost 8% Higher on TuesdayThe Motley Fool · Sep 29, 2026
- Stifel upgrades STAAR Surgical to Buy from HoldFintel · Sep 29, 2026
- Why Staar Surgical Stock Soared TodayThe Motley Fool · Sep 25, 2026
The company
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for over 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 4 million ICLs in over 85 countries. Headquartered in Lake Forest, California, the Company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.discoverICL.com .
- Sector
- Health Care
- Industry
- Ophthalmic Goods
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- staar.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.